Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide for Treating Sepsis with Heart Failure: A Systematic Review and Meta-Analysis - Takeaways - MDSpire

Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide for Treating Sepsis with Heart Failure: A Systematic Review and Meta-Analysis

  • By

  • Wei Liu

  • Ruixiang Zeng

  • Zhilin Zhang

  • Xiangzhao Kong

  • Liheng Guo

  • Biao Cai

  • March 7, 2026

  • 0 min

Share

  • 1

    Sepsis complicated by heart failure (SCHF) significantly contributes to multiple organ failure and has high mortality rates ranging from 36% to 55%.

  • 2

    Recombinant human brain natriuretic peptide (rhBNP) shows promise in preclinical studies for reducing myocardial injury and mortality in septic models.

  • 3

    Clinical efficacy of rhBNP in SCHF remains controversial, with some studies indicating reduced 28-day mortality while others show no significant survival improvement.

  • 4

    This systematic review and meta-analysis aims to evaluate the efficacy and safety of rhBNP in treating SCHF based on randomized controlled trials.

  • 5

    The study protocol was registered on PROSPERO and amended to extend the literature search period to ensure inclusion of the most current evidence.

Original Source(s)

Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide for Treating Sepsis with Heart Failure: A Systematic Review and Meta-Analysis

  • by Wei Liu, Ruixiang Zeng, Zhilin Zhang, Xiangzhao Kong, Liheng Guo, Biao Cai

  • March 7, 2026

Related Content

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

Cardiac magnetic resonance biomarkers for cardiovascular complications in diabetes: a systematic review and meta-analysis